Authors
Latest:
Brexucabtagene Autoleucel in R/R Mantle Cell LymphomaExperts discussed the ZUMA-2 clinical trial of brexucabtagene autoleucel.
Latest:
Deepu Madduri, MD, on the Design of the Phase 1b/2 CARTITUDE-1 TrialThe goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.
Latest:
Dr. Ruan on Future Research With CAR T-Cell Therapy in MCLJia Ruan, MD, PhD, discusses future research with CAR T-cell therapy in mantle cell lymphoma.
Latest:
Jason Westin, MD, FASCP, on the Potential Impact of Predicting Toxicity for CAR-T TreatmentThe director of the Lymphoma Clinical Research Program at University of Texas MD Anderson Cancer Center discussed axi-cel's safety profile and an important factor for improving access to CAR-T therapies.
Latest:
Reinfusion of CAR T Therapy Shows Promise in B-ALLLong term survival was limited and all patients with B-cell acute lymphoblastic leukemia eventually relapsed.
Latest:
Novartis's CAR-T Tisagenlecleucel Continues to Show Efficacy for R/R Follicular Lymphoma in Long-Term Follow-UpThe CAR-T, marketed as Kymriah, showed a 4-year overall survival rate of 79.3% and a median progression-free survival of 53.3 months.
Latest:
Durable Response Seen With Axi-Cel in Non-Hodgkin LymphomaIn this population, median progression-free survival was nearly 40 months.
Latest:
Determining Order of CAR T Therapy: Elias Jabbour, MD; Jae Park, MDThe oncologists from MD Anderson and Memorial Sloan Kettering Cancer Centers discuss sequencing CAR T-cell therapies and other key therapies in patients with B-cell acute lymphoblastic leukemia.
Latest:
Dr. Jagannath on CAR T-Cell Therapy for Multiple MyelomaSundar Jagannath, MD, director of the Multiple Myeloma program and professor of medicine at the Tisch Cancer Institute, Mount Sinai, discusses chimeric antigen receptor (CAR) T-cell therapy for patients with multiple myeloma.
Latest:
Dr. Abramson on TRANSCEND on JCAR017 Therapy in NHLJeremy S. Abramson, MD, clinical director, Center for Lymphoma, Massachusetts General Hospital, discusses the TRANSCEND study, which is exploring the CD19-directed chimeric antigen receptor (CAR) T-cell therapy JCAR017 in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma (NHL).
Latest:
Dr. Cohen on CAR T-Cell Therapy for Head and Neck CancerEzra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses CAR T-cell therapy for patients with head and neck cancer.
Latest:
Immunotherapy and CAR T-Cell Therapy: Stephen M. Ansell, MD, PhDThe chair of the Lymphoma Group at Mayo Clinic discussed incorporating immunotherapies beyond CAR T-cell therapy in non-Hodgkin lymphoma.
Latest:
Dr. Roboz on Challenges With CAR T-cell Therapy in ALLGail Roboz, MD, a professor of Medicine and director of the Clinical and Translational Leukemia Program at Weill Cornell Medicine/NewYork-Presbyterian Hospital, discusses the challenges clinicians are facing with chimeric antigen receptor (CAR) T-cell therapy in acute lymphoblastic leukemia (ALL).
Latest:
Dr. Martin on the Utility of CAR T-Cell Therapy in High-Risk MCLPeter Martin, MD, discusses selecting treatment for patients with high-risk mantle cell lymphoma.
Latest:
Dr. Karmali on the Impact of CAR T-Cell Therapy in DLBCLReem Karmali, MD, Feinberg School of Medicine, Northwestern University, discusses the impact of chimeric antigen receptor (CAR) T-cell therapy on the treatment of patients with diffuse large B-cell lymphoma (DLBCL).
Latest:
Dr. Sasine on Predicting Individual Benefit with CAR T CellsJoshua P. Sasine, MD, PhD, discusses the challenges in predicting a patient’s individual benefit with CAR T-cell therapy in hematologic malignancies.
Latest:
Emerging CAR T-Cell Therapies in Hematologic CancersXiuli Wang, PhD, discusses emerging CAR T-cell therapy in hematologic cancers.
Latest:
Dr. Hammers on Challenges With CAR T-Cell Therapy in RCCHans Hammers, MD, PhD, associate professor of internal medicine, Division of Hematology-Oncology, UT Southwestern Medical Center, discusses the challenges with using CAR T-cell therapy in renal cell carcinoma.
Latest:
Dr. Frey on CAR T-Cell Therapy in High-Risk ALLNoelle Frey, MD, MSCE, discusses the use of CAR T-cell therapy in acute lymphocytic leukemia.
Latest:
Dr. Avigan on BCMA-Targeted CAR T-Cell Therapy in Multiple MyelomaDavid E. Avigan, MD, professor of medicine, Harvard Medical School, and active staff, Hematology-Oncology, Beth Israel Deaconess Medical Center, discusses BCMA-targeted CAR T-cell therapy in multiple myeloma.
Latest:
John DiPersio, MD, PhD, on Ongoing Advancements in Stem Cell Transplantation and Cell TherapyThe director of the Center for Gene and Cellular Immunotherapy at Washington University School of Medicine discussed novel innovations that lie on the horizon.
Latest:
Dr. Mato on Utilizing CAR T Cells in CLLAnthony R. Mato, MD, MSCE, discusses where CAR T cell-therapy will fit into the treatment paradigm of chronic lymphocytic leukemia.
Latest:
Cohort Data From TRANSCEND-CLL-004 of Liso-Cel: William G. Wierda, MDThe associate professor of medicine from MD Anderson Cancer Center discussed data from the phase 1 cohort of liso-cel combined with ibrutinib.
Latest:
Dr. Siddiqi on the Rationale to Evaluate CAR T-Cell Therapy in CLLTanya Siddiqi, MD, discusses the rationale to evaluate CAR T-cell therapy in chronic lymphocytic leukemia.
Latest:
Sham Mailankody, MBBS, on Further Research With ALLO-715The associate attending physician at Memorial Sloan Kettering Cancer Center discussed further research that remains to be conducted with the allogeneic cell therapy.
